Filtered By:
Condition: Heart Failure
Therapy: Stem Cell Therapy

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 70 results found since Jan 2013.

Synergistic Effects of Combined Cell Therapy for Chronic Ischemic Cardiomyopathy
BackgroundBoth bone marrow–derived mesenchymal stem cells (MSCs) and c-kit+ cardiac stem cells (CSCs) improve left ventricular remodeling in porcine models and clinical trials. Using xenogeneic (human) cells in immunosuppressed animals with acute ischemic heart disease, we previously showed that these 2 cell types act synergistically.ObjectivesTo more accurately model clinical applications for heart failure, this study tested whether the combination of autologous MSCs and CSCs produce greater improvement in cardiac performance than MSCs alone in a nonimmunosuppressed porcine model of chronic ischemic cardiomyopathy.Metho...
Source: Journal of the American College of Cardiology: Cardiovascular Imaging - October 26, 2015 Category: Radiology Source Type: research

Transfusion strategy in hematological intensive care unit: study protocol for a randomized controlled trial
Background: Packed red blood cell (PRBC) transfusion is required in hematology patients treated with chemotherapy for acute leukemia, autologous (auto) or allogeneic (allo) hematopoietic stem cell transplantation (HSCT). In certain situations like septic shock, hip surgery, coronary disease or gastrointestinal hemorrhage, a restrictive transfusion strategy is associated with a reduction of infection and death. A transfusion strategy using a single PRBC unit has been retrospectively investigated and showed a safe reduction of PRBC consumption and costs. We therefore designed a study to prospectively demonstrate that the tra...
Source: Trials - November 23, 2015 Category: Journals (General) Authors: Sylvain ChantepieJean-Baptiste MearLydia GuittetBenoît DervauxJean-Pierre MarolleauFabrice JardinJean-Jacques DutheilJean-Jacques ParientiJean-Pierre VilqueOumedaly Reman Source Type: research

Combining patient proteomics and in vitro cardiomyocyte phenotype testing to identify potential mediators of heart failure with preserved ejection fraction
Conclusions: Platelets may harbor proteins associated with HFpEF. S100A8 is present in the platelets of subjects with HFpEF and increased in the plasma of the same subjects. We further established a bedside-to-bench translational system that can be utilized as a secondary screen to ascertain whether the biomarkers may be an associated finding or causal to the disease process. S100A8 has been linked with other cardiovascular disease such as atherosclerosis and risk for myocardial infarction, stroke, or death. This is the first report on association of S100A8 with HFpEF.
Source: Journal of Translational Medicine - January 20, 2016 Category: Research Authors: Roseanne RaphaelDiana PurushothamCourtney GastonguayMarla ChesnikWai-Meng KwokHsiang-En WuSanjiv ShahShama MirzaJennifer Strande Source Type: research

Developments in the management of Chagas cardiomyopathy.
Authors: Tanowitz HB, Machado FS, Spray DC, Friedman JM, Weiss OS, Lora JN, Nagajyothi J, Moraes DN, Garg NJ, Nunes MC, Ribeiro AL Abstract Over 100 years have elapsed since the discovery of Chagas disease and there is still much to learn regarding pathogenesis and treatment. Although there are antiparasitic drugs available, such as benznidazole and nifurtimox, they are not totally reliable and often toxic. A recently released negative clinical trial with benznidazole in patients with chronic Chagas cardiomyopathy further reinforces the concerns regarding its effectiveness. New drugs and new delivery systems, incl...
Source: Expert Review of Cardiovascular Therapy - February 17, 2016 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research

Regenerative firm Creative Medical launches cardio-focused AngioStem biz
Regenerative biotech company Creative Medical Health said today it is launching a subsidiary biz, AngioStem, to commercialize its cardiovascular assets. Assets on hand for the newly launched company include a therapy that uses autologous and allogeneic adult stem cells in combination with modulation of oxidative stress to treat heart failure in patients with cardiovascular disease, Creative Medical Health said. “At Creative Medical Health, our mission is to identify promising technologies, add value by strengthening the science and intellectual property surrounding the technologies, and subsequently spin off new com...
Source: Mass Device - February 29, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Cardiovascular Regenerative Medicine AngioStem Creative Medical Health Source Type: news

Quantitative Magnetic Particle Imaging Monitors the Transplantation, Biodistribution, and Clearance of Stem Cells In Vivo
Stem cell therapies have enormous potential for treating many debilitating diseases, including heart failure, stroke and traumatic brain injury. For maximal efficacy, these therapies require targeted cell delivery to specific tissues followed by successful cell engraftment. However, targeted delivery remains an open challenge. As one example, it is common for intravenous deliveries of mesenchymal stem cells (MSCs) to become entrapped in lung microvasculature instead of the target tissue. Hence, a robust, quantitative imaging method would be essential for developing efficacious cell therapies. Here we show that Magnetic Par...
Source: Theranostics - June 5, 2016 Category: Molecular Biology Authors: Bo Zheng, Marc P. von See, Elaine Yu, Beliz Gunel, Kuan Lu, Tandis Vazin, David V. Schaffer, Patrick W. Goodwill, Steven M. Conolly Tags: Research Paper Source Type: research

Long Distance Running Effects On Your Health
Long distance running is becoming more and more popular. Close to two million people every year drag themselves across the finish lines. And that’s just in half marathon races. Runners in these 13.1 mile events have increased six-fold over the past 25 years.  All these amateur athletes think they’re getting really healthy as they work themselves up to full marathons. But the truth is they are cutting years off their life.  You can see it for yourself if you stand at the finish line of any race. The hardcore runners look terrible. They look gaunt and malnourished. They are hunched over and have a stiff awkwa...
Source: Al Sears, MD Natural Remedies - June 20, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Fitness Source Type: news

Peripheral blood mononuclear cell secretome for tissue repair
AbstractFor almost two decades, cell-based therapies have been tested in modern regenerative medicine to either replace or regenerate human cells, tissues, or organs and restore normal function. Secreted paracrine factors are increasingly accepted to exert beneficial biological effects that promote tissue regeneration. These factors are called the cell secretome and include a variety of proteins, lipids, microRNAs, and extracellular vesicles, such as exosomes and microparticles. The stem cell secretome has most commonly been investigated in pre-clinical settings. However, a growing body of evidence indicates that other cel...
Source: Apoptosis - September 30, 2016 Category: Molecular Biology Source Type: research

Stem Cell Therapies for Cardiovascular Diseases: What Does the Future Hold?
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality around the globe. In Australia, one in six people are affected by CVD and a total of 4.2 million people are suffering from heart disease, stroke or vascular disease. Coronary artery disease affects around 1.2 million Australians, many of whom develop chronic heart failure as a result of ischaemic cardiomyopathy. The management of CVD has evolved tremendously in the past three decades, but the majority of treatments are not curative.
Source: Heart, Lung and Circulation - January 24, 2017 Category: Cardiology Authors: Hai-Ying Chen, Padraig Michael Strappe, Le-xin Wang Tags: Editorial Source Type: research

Assessment of stability of CD34+ cell products enriched by immunoselection from peripheral blood mononuclear cells during refrigerated storage
Haematopoietic stem cell transplantation is generally used for haematopoietic regeneration after myeloablative therapy [1]. Therapeutic effects of stem cells in other diseases like heart failure [2,3], bone healing [4], chronic spinal cord injuries [5], retinal disorders [6], stroke [7], refractory Crohn disease [8] and multiple sclerosis [9] are being investigated in various clinical studies. Haematopoietic stem cells are most often collected in a mononuclear cell fraction by leukapheresis from peripheral blood.
Source: Transfusion and Apheresis Science - July 21, 2017 Category: Hematology Authors: Metka Krasna, Elvira Malicev, Jasmina Ziva Rozman, Bojan Vrtovec Source Type: research

Stem Cell Factor Tied to Reduced Risk of Cardiac Events, Death
High levels of SCF linked to lower cardiovascular and all - cause mortality, heart failure, stroke
Source: Pulmonary Medicine News - Doctors Lounge - September 1, 2017 Category: Respiratory Medicine Tags: Cardiology, Internal Medicine, Pathology, Pulmonology, Journal, Source Type: news

Therapeutic Effects of Mesenchymal Stem Cell-Derived Exosomes in Cardiovascular Disease.
Authors: Suzuki E, Fujita D, Takahashi M, Oba S, Nishimatsu H Abstract Mesenchymal stem cells (MSCs) are multipotent stem cells that reside in various organs. They have the capacity to differentiate into various cell types, including cardiomyocytes, vascular endothelial cells, and vascular smooth muscle cells. Among the various MSCs, bone marrow-derived MSCs (BMMSCs) have been widely used for treating acute myocardial infarction (AMI) and ischemic heart failure (IHF) in preclinical and clinical studies. Although the beneficial effects of BMMSCs in treating AMI and IHF were originally attributed to their capacity to...
Source: Advances in Experimental Medicine and Biology - September 24, 2017 Category: Research Tags: Adv Exp Med Biol Source Type: research

Safety and Efficacy of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients with ST-segment Elevation Myocardial Infarction and Left Ventricular Dysfunction: A Multicenter Randomized, Double-Blind and Placebo-Controlled Clinical Trial.
Conclusions: Allogeneic cardiac stem cells can be safely administered in STEMI patients with LV dysfunction early after revascularization. Low immunogenicity and absence of immune-mediated events will facilitate adequately powered studies to demonstrate their clinical efficacy in this setting.Clinical Trial Registration: NCT 02439398. PMID: 29921651 [PubMed - as supplied by publisher]
Source: Circulation Research - June 19, 2018 Category: Cardiology Authors: Fernández-Avilés F, Sanz-Ruiz R, Bogaert J, Casado Plasencia A, Gilaberte I, Belmans A, Fernández-Santos ME, Charron D, Mulet M, Yotti R, Palacios I, Luque M, Sádaba R, San Roman JA, Larman M, Sánchez PL, Sanchis J, Jimenez-Navarro MF, Claus P, Al-Da Tags: Circ Res Source Type: research

Changing Incidence of Major Cardiovascular Events in Multiple Myeloma Patients over Time
Conclusion: CVD is a common complication in MM patients: within 5 years of a MM diagnosis, over 25% develop CVD requiring hospitalization. Contrary to our hypothesis, we did not find increased CVD admissions in the most recent era. Decreased admissions due to CHF and CAD in the most recent era of diagnosis may indicate a greater awareness of this issue, routine thromboprophylaxis with anti-platelet agents in patients being treated with immunomodulatory agents, or changes in secular trends in the diagnosis and treatment of CVD. CVD is an ongoing source of morbidity for MM patients requiring further study and the vigilance o...
Source: Blood - November 21, 2018 Category: Hematology Authors: Rosenberg, A. S., Li, Q., Brunson, A. M., Tuscano, J., Wun, T., Keegan, T. H. M. Tags: 904. Outcomes Research-Malignant Conditions: Poster II Source Type: research

Scientists discover new type of immune cells that are essential for forming heart valves
UCLA researchers have identified for the first time the origin of an immune cell that plays a critical role in the formation of healthy heart valves. The findings could pave the way for new treatments for heart valve disorders, which can be caused by congenital defects, aging or disease.Their study, led by Dr. Atsushi “Austin” Nakano, a UCLA associate professor of molecular, cell and developmental biology and member of theEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, was published in the journal Developmental Cell.Building on previous research by Nakano, which showed that the embr...
Source: UCLA Newsroom: Health Sciences - February 21, 2019 Category: Universities & Medical Training Source Type: news